Celltrion Group’s honorary chairman retired “Don’t forget me, I will be with you as a shareholder”
[팍스넷뉴스 민승기 기자] Celltrion Group Honorary Chairman Seo Jeong-jin said to shareholders and employees,’It was an honor. Don’t forget me,’ he officially announced his retirement.
Honorary Chairman Seo made a final greeting with shareholders through a phone connection at the Celltrion Regular Shareholders’ Meeting held at 10 am on the 26th at Songdo Convensia, Incheon.
Honorary Chairman Seo said, “I wasn’t a great patriot, I wasn’t a person with great corporate management values. As the company grew, I started thinking about what the right company was, and that made my retirement decision.” He said, “According to the textbook, as stipulated by the commercial law, the company must be a company of shareholders and employees,” he said. He added, “From now on, I will be a person who sits in the same seat at the shareholders’ meeting as regular shareholders, rebuking and encouraging the management of the company.”
On this day, Honorary Chairman Seo also revealed his plans to advance into Europe, the Corona 19 antibody treatment drug, Rekirona. “Within a day or two, there will be positive results from the EMA (regarding the Leckirona state),” he said. “I don’t know how the results will come out, but there are signs that it will be good news.” He explained that when the state of Rekirona receives emergency approval from EMA, it knocks on the US market based on the data.
Honorary Chairman Seo explained, “The reason we first challenged the European market, not the United States, was to reduce the risk. In the United States, we already tried to enter the European market because there are already corona19 antibody treatments developed by domestic pharmaceutical companies.” did.
It also explained the Celltrion research plan for the mutant Corona 19 virus. Honorary Chairman Seo said, “Corona 19 will be difficult to end this year due to the effects of mutant viruses.”
ⒸLook at the market with new eyes. Unauthorized distribution of Paxnet News is prohibited